CClinicalTrials.gg
RecruitingNCT07257913GutMilkUpdated Dec 2, 2025

Impact of Dairy Integration Into Canadian Food Guide on Gut Health

An interventional study of Milk and Fermented milk in Gut Epithelial Permeability, Gut Microbiota Composition and Diversity and Gut and Circulating Inflammatory Markers, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Laval University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

The primary objective is to investigate the impact of milk, fermented milk, and soy beverages, incorporated in a diet reflecting adherence to Canadian food guide recommendations on food choices on gut microbiota in middle-aged adults (45-65 years) with abdominal obesity and slightly deteriorated lipids and/or glucose profile. The study aims to discern whether the integration of soy beverages (control), milk, and fermented milk within the CFG diet contributes to distinct gut outcomes and alterations in gut health. We hypothesized that milk and fermented milk will further promote beneficial changes in gut health parameters including gut microbiota composition, trans-epithelial permeability, and inflammation, relative to soy beverages.

Read the detailed description

Single-blinded crossover RCT to test the impact of integrating dairy (i.e., milk and fermented milk) into the Canadian Food Guide (CFG) diet on gut health, in fully controlled dietary settings. The trial will include mid-age women and men with abdominal obesity and slightly deteriorated metabolic profile (n=20). The trial will feature 3 controlled-feeding phases (14 days), allocated in a random order and separated by free-uncontrolled feeding washout periods (14-28 days). Each dietary intervention phase will be initiated by a Run-in full-feeding period (4 days), to standardize participants' dietary intakes, and immediately followed by one of the 3 dietary interventions (9 days) reflecting adherence to the CFG recommendation (9 days, CFG-Diet) incorporating either soy beverages (Control), milk, or non-effervescent fermented milk.

This approach was shown to be highly informative in deciphering the interaction between diet and the gut microbiota in previous work. It will be able to assess how integrating dairy (i.e., milk and fermented milk) into the Canadian Food Guide (CFG) diet promptly modulates gut health parameters (i.e. gut microbiota composition, inflammatory states, and gut permeability) in the context of obesity and metabolic complications, relative to a plant-based alternative. The fully controlled dietary setting of this study design will provide precise intakes of foods and bioactive nutrients, which will enable us to comprehensively assess the impact of dairies on gut health.

The trial will include 10 women and 10 men with abdominal obesity and slightly deteriorated metabolic profile.

Diet sequence allocation will be randomized with a sex-specific stratification. The study will be single-blinded, such as participants will not be informed of the precise nature of the diet sequence.

TRIAL INTERVENTION PHASES (3 X 14 DAYS)

During each intervention phases, all meals and foods will be provided to ensure optimal diet control. Each intervention phases will follow this sequence:

  • Day 0: Initiation of the run-in full-feeding period (4 days) to standardize participants' dietary intakes.
  • Day 4: Baseline sampling and data collection.
  • Day 4: Initiation of the CFG dietary intervention (10 days) incorporating either soy beverages (Control), milk, or non-effervescent fermented milk.
  • Day 6: Post-intervention (+2 days) sampling and data collection.
  • Day 13: Post-intervention (+9 days) sampling and data collection. End of the intervention phases.
02

Conditions studied

  • Gut Epithelial Permeability
  • Gut Microbiota Composition and Diversity
  • Gut and Circulating Inflammatory Markers
  • Milk and Digestion

Browse trials for

Keywords

  • Milk consumption
  • Gut epithelial permeability
  • Inflammation
  • Gut microbiota
03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 2,437 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Laval University is the lead sponsor of 371 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • IMC \< 45
  • Waist circumference > 80 cm (Women) or 94 cm (men)

Exclusion criteria

Exclusion Criteria:

  • History of diabetes (types 1 and 2), CVD, enteropathy, immune diseases or bariatric surgery
  • Cancer (diagnostic and/or treatment) during the last 5 years
  • Antibiotic consumption during the last 3 months
  • Active smoking or cannabis consumption
  • Lactose intolerance or allergy, any allergies to foods given in the intervention phases
  • Irregular defecation patterns
  • Pregnancy/lactation
  • Inability to speak French
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Milk

    \- Consumption of milk 3 times per day during 9 days alongside CFG diet, following a 4 day control diet

    Other: Milk · Other: Fermented milk · Other: Soy beverage

  • Experimental
    Fermented milk

    \- Consumption of fermented milk 3 times per day during 9 days alongside CFG diet, following a 4 day control diet

    Other: Milk · Other: Fermented milk · Other: Soy beverage

  • Experimental
    Soy beverage

    \- Consumption of a soy beverage 3 times per day during 9 days alongside CFG diet, following a 4 day control diet

    Other: Milk · Other: Fermented milk · Other: Soy beverage

Interventions

  • OtherMilk

    Consumption of 1 cup milk 3 times per day during 9 days alongside CFG diet

  • OtherFermented milk

    Consumption of fermented milk 3 times per day during 9 days alongside CFG diet

  • OtherSoy beverage

    Consumption of a soy beverage 3 times per day during 9 days alongside CFG diet

06

What researchers measure

Primary outcomes

  1. Gut epithelial permeability

    Post-intervention lactulose/mannitol ratio by LCMS, 0-5 hours after ingestion of the non-metabolizable sugar

    Time frame: This outcome will be measured on the last day (day 13) of each intervention phase.

Secondary outcomes

  1. Gut inflammatory markers

    Fecal calprotectin levels by ELISA

    Time frame: Samples will be collected on days 6 and 13 of each intervention phase.

  2. Perceived gut symptoms

    Perception gastrointestinal symptoms questionnaires

    Time frame: Gastrointestinal symptoms questionnaire is administered on days 0, 4 and 13.

  3. Whole gut transit time

    Whole gut transit time (h) by the Blue poop challenge

    Time frame: At days 1, 4 and 11.

07

Study locations

1 of 1 sites recruiting
  • Institute of Nutrition and Functional Foods (INAF)
    Québec, Quebec G1V 0A6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07257913
Lead sponsor
Laval University
Responsible party
Alain Veilleux (Full professor, Laval University) — Principal investigator
First posted
Dec 2, 2025
Start date
Oct 6, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Alain Veilleux, PhD
Contact
alain.veilleux@fsaa.ulaval.ca
418 656-2131 ext. 405108
Alain Veilleux, PhD
principal investigator · Laval University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion